Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Clinical trials sits at the center of this dementia and brain health question.
Yes, clinical trials offer genuine hope for Alzheimer’s disease, though that hope comes with important caveats. Recent advances have produced the first disease-modifying treatments that actually slow cognitive decline in early-stage patients, moving beyond symptom management for the first time in decades. Lecanemab (Leqembi), approved by the FDA in 2023, demonstrated a 27% slowing of cognitive decline over 18 months in people with mild cognitive impairment or mild dementia—a modest but measurable difference that represents a watershed moment in Alzheimer’s research.
However, clinical trials are not cures, and they reveal uncomfortable truths alongside progress. These new treatments work best in people diagnosed very early, require regular infusions or medications, and carry risks including amyloid-related imaging abnormalities (ARIA), a potentially serious side effect visible only on brain scans. The real hope from trials lies not in reversing Alzheimer’s, but in understanding which approaches delay it, allowing patients and families to make informed choices based on their own circumstances.
Table of Contents
- How Are Clinical Trials Changing What We Know About Alzheimer’s Treatment?
- What Do Clinical Trials Reveal About the Limits of Current Treatments?
- What Do Trials Tell Us About Who Benefits Most From New Alzheimer’s Treatments?
- How Should Clinical Trial Results Influence Care Decisions for Someone With Mild Cognitive Impairment?
- What Warnings and Uncertainties Remain From Clinical Trial Data?
- What New Approaches Are Emerging From Recent Clinical Trials?
- What Does the Future of Alzheimer’s Clinical Trials Look Like?
- Conclusion
- Frequently Asked Questions
How Are Clinical Trials Changing What We Know About Alzheimer’s Treatment?
clinical trials have fundamentally shifted Alzheimer’s research from focusing solely on what happens after diagnosis to preventing or delaying the disease before major symptoms appear. Traditional drug development for Alzheimer’s relied on testing medications in people with moderate-to-severe dementia, where the brain damage was already extensive. Over 99% of drugs developed this way failed. Trials over the past five years have instead enrolled people in preclinical or early stages—those with amyloid buildup in the brain but no symptoms, or with mild cognitive changes—and measured whether treating them earlier makes a difference.
The CLARITY AD trial tested lecanemab in this early population and produced results that shifted clinical practice. A 27% slowing of decline translates to about 5 months of preserved cognition over an 18-month period in real terms, which matters to families watching someone progress from remembering to forget important information. The trial also tested aducanumab (Aduhelm), which was approved and then largely abandoned after data suggested it didn’t help patients. That failure illustrates a crucial limitation: not every drug that reduces amyloid in the brain actually helps people.
What Do Clinical Trials Reveal About the Limits of Current Treatments?
One of the most important findings from recent trials is that targeting amyloid alone, even successfully, doesn’t reverse Alzheimer’s once cognitive decline begins. The trials show slowing, not stopping or reverting. In CLARITY AD, even the lecanemab group experienced measurable cognitive decline over 18 months; the treatment just made it happen more slowly. This is a significant limitation because it means trials can only help people diagnosed early, before substantial brain damage has occurred, and even then the benefit is partial.
Another critical limitation revealed by trials is the emergence of amyloid-related imaging abnormalities, or ARIA. People on lecanemab have shown microhemorrhages or microinfarcts on brain MRI scans, visible damage that sometimes causes headaches, confusion, or visual disturbances. The trials showed that older age, female sex, and carrying the APOE4 genetic risk factor increase ARIA risk substantially. Some trial participants experienced serious events, including one death in a trial participant with concurrent medical conditions, highlighting that these are not benign treatments. Many patients require regular MRI monitoring, adding cost and logistical burden.
What Do Trials Tell Us About Who Benefits Most From New Alzheimer’s Treatments?
Clinical trials have revealed stark differences in who actually benefits from emerging treatments, creating a sort of “window of opportunity” that matters for real decision-making. Lecanemab works best in people with documented amyloid in the brain (confirmed by PET scan or certain CSF or blood tests), cognitive decline that is still mild, and relatively intact brain structure on MRI. Trials excluded people with significant medical conditions, dementia from other causes, or moderate-to-severe cognitive impairment. In other words, trials are enrolling people who are already in the earlier stages and often healthier than the general population.
This creates a practical limitation: many people diagnosed with Alzheimer’s in clinical practice don’t fit the trial population profile. Someone with moderate dementia, heart failure, or kidney disease may not be eligible for lecanemab based on trial safety data. Trials are also limited by the requirement for frequent infusions (lecanemab requires monthly or biweekly IV infusions) or complex monitoring, which assumes access to specialized treatment centers and the ability to commit to years of appointments. For rural patients or those with transportation barriers, these logistical challenges may render trial-tested treatments impractical regardless of efficacy.
How Should Clinical Trial Results Influence Care Decisions for Someone With Mild Cognitive Impairment?
The practical question families face is whether trial results translate to real benefit for their specific loved one, and the honest answer requires detailed conversation with a neurologist or memory specialist. If someone has mild cognitive impairment or mild dementia, documented amyloid pathology, and no contraindications, lecanemab offers the only disease-modifying option with evidence of slowing progression. The tradeoff is accepting monthly infusions for at least 18 months (current trials show most benefit within that window), regular MRI monitoring for safety, potential side effects, and costs that may not be fully covered by insurance. For someone with preclinical Alzheimer’s—amyloid in the brain but no cognitive symptoms—the calculus differs entirely.
Several major trials are currently enrolling these patients to test whether treating asymptomatic people prevents or delays symptoms. The logic is sound: treat before damage accumulates. But the tradeoff involves committing to years of treatment for a disease that may never cause noticeable symptoms in that person’s lifetime, with unknown long-term safety data. Clinical trials haven’t yet resolved whether this population benefits enough to recommend universal screening and early treatment.
What Warnings and Uncertainties Remain From Clinical Trial Data?
The most important warning from trials is that they measure what happens in carefully controlled settings with selected populations over defined periods, typically 18 months. Long-term safety and efficacy data for newer Alzheimer’s treatments remain limited. Lecanemab was approved based on 18-month data, but what happens at 3 years, 5 years, or beyond remains unknown from the trials. Some patients have experienced worsening confusion, headaches, or vision changes related to ARIA, and while these resolved in most cases, the unpredictability creates anxiety for patients and families.
Another critical uncertainty involves combination therapy. Most trials test single drugs, but Alzheimer’s involves multiple pathological processes—amyloid, tau tangles, neuroinflammation, and others. Clinical trials haven’t yet definitively established which combinations of drugs might work better than single agents, or whether combining treatments increases side effects unacceptably. Patients considering treatment based on trial data should understand they’re participating in an ongoing medical experiment; benefit is real but partial, and longer-term outcomes remain unknown.
What New Approaches Are Emerging From Recent Clinical Trials?
Beyond amyloid-targeting drugs like lecanemab, trials are now testing drugs that target tau tangles, another hallmark of Alzheimer’s pathology. Remternetug (now called GLP-1 receptor agonists) and other novel mechanisms are in various trial phases, examining whether addressing tau prevents or slows cognitive decline. Some trials are also exploring blood-based biomarkers to identify people at risk before symptoms appear, potentially expanding the population that could benefit from early intervention.
One promising trial approach involves combination therapy from the start. Rather than testing one mechanism at a time, some newer trials enroll patients to receive anti-amyloid treatment plus tau-targeting therapy, with the theory that hitting multiple pathways simultaneously might produce larger benefits. These trials are still ongoing, but they represent a shift toward more aggressive, earlier intervention in people identified as high-risk through blood or genetic testing.
What Does the Future of Alzheimer’s Clinical Trials Look Like?
The trajectory suggests continued focus on earlier intervention, earlier detection, and combination therapies. Trials in progress will likely establish whether treating preclinical or asymptomatic populations is worthwhile, answering a question that will reshape how many people receive Alzheimer’s treatment. Advances in blood-based biomarkers may make screening for amyloid pathology as routine as cholesterol testing, expanding the pool of potential trial participants and treatment candidates dramatically.
One forward-looking development is the emphasis on prevention trials—testing whether medications or interventions can prevent Alzheimer’s from developing in people at high genetic risk. These mega-trials are recruiting thousands of cognitively normal people and following them for years, comparing active drug to placebo. Results from these trials could eventually make Alzheimer’s more like heart disease or diabetes: something screened for and managed prophylactically in at-risk people, rather than primarily addressed after symptomatic decline begins.
Conclusion
Clinical trials have fundamentally changed Alzheimer’s from an untreatable disease to one where early intervention can measurably slow decline, offering real but modest hope grounded in evidence. Lecanemab and similar drugs represent genuine progress, moving beyond symptom management to disease modification. However, this hope is available primarily to people diagnosed early, comfortable with frequent medical appointments and monitoring, and without significant contraindications—a narrower population than many expect.
The most important takeaway from recent clinical trials is that timing, early detection, and realistic expectations matter as much as the drugs themselves. Families considering trial-based treatments should work with a neurologist to understand whether their loved one fits the profile of trial participants likely to benefit, weigh the documented tradeoffs carefully, and recognize that current trials measure benefit over months to years, not decades. As new trials unfold over the next several years, the landscape will shift again—likely offering more options, but also asking more questions about who should be treated and when.
Frequently Asked Questions
If my parent has mild cognitive impairment, should they start lecanemab based on clinical trial results?
That depends on whether they have documented amyloid pathology (confirmed by PET scan, CSF testing, or blood biomarkers), whether their cognitive decline is still mild, and their overall health and ability to tolerate monthly infusions with regular MRI monitoring. Clinical trials showed benefit in this population, but trials enrolled relatively healthy, highly selected patients. A neurologist specializing in memory disorders can help determine if your parent matches the trial population and whether the modest slowing of decline justifies the commitment.
What is ARIA, and how common is it in people taking lecanemab?
ARIA stands for amyloid-related imaging abnormalities—microhemorrhages or tiny infarcts visible on MRI in people on amyloid-targeting drugs. In lecanemab trials, ARIA occurred in about 12-17% of patients, with most cases asymptomatic (visible on MRI but causing no symptoms). However, older patients, women, and APOE4 carriers had higher rates. Symptomatic ARIA is less common but can cause headaches, confusion, or vision changes. Regular MRI monitoring can detect ARIA early, allowing doctors to adjust or stop treatment if necessary.
Why don’t clinical trials test treatments in people with moderate or severe dementia?
By the time dementia becomes moderate or severe, substantial brain damage and neurodegeneration have already occurred. Clinical trials found that drugs targeting single pathways (like amyloid) don’t reverse this damage effectively. Trials focus on earlier stages because that’s where the evidence shows these treatments can delay decline. Additionally, people with moderate-to-severe dementia often have other medical conditions or take medications that complicate trial participation, making them ineligible for safety reasons.
Are there clinical trials recruiting people right now for new Alzheimer’s treatments?
Yes. Several major trials are actively recruiting people with preclinical Alzheimer’s (amyloid pathology but no symptoms), mild cognitive impairment, and early dementia. You can search ClinicalTrials.gov for “Alzheimer’s disease” filtered by your location and stage of disease. Be aware that recruitment criteria are specific—you’ll need cognitive testing, biomarker confirmation, and often MRI screening. Your neurologist can help identify which trials your loved one might qualify for.
What is the difference between slowing cognitive decline and stopping it?
Slowing decline means the progression of memory loss and cognitive impairment continues, but more slowly than it would without treatment. In lecanemab trials, patients still experienced measurable cognitive decline over 18 months; the drug didn’t prevent or reverse decline, it just made it happen at about 27% slower pace. For some families, 5 months of preserved cognition over 18 months represents significant value. For others, continuing to decline, even slowly, feels like inadequate benefit relative to the burden of treatment.
Should I pursue genetic testing if Alzheimer’s runs in my family?
If multiple family members have been diagnosed with Alzheimer’s at relatively young ages (under 60), genetic testing for familial Alzheimer’s disease genes (APP, PSEN1, PSEN2) may be appropriate and could influence your eligibility for trials or preventive treatment in the future. However, most Alzheimer’s disease is not inherited in this clear Mendelian pattern. APOE4 genetic testing is available but more common as a research tool. Discuss genetic testing options with a genetic counselor or neurologist who can explain the implications for you and your family.
You Might Also Like
- Why Ethics Matter in Alzheimer’s Clinical Trials
- How Friends Can Support a Family Facing Dementia
- How Families Can Support Civic Participation Safely
For more, see National Institute on Aging.
